JAMA April 02, 2019

Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial

Packer DL, Mark DB, Robb RA, et al.

Bottom Line

In symptomatic atrial fibrillation, catheter ablation did not significantly reduce the composite primary endpoint of death, disabling stroke, serious bleeding, or cardiac arrest compared to medical therapy, though it significantly reduced atrial fibrillation recurrence and cardiovascular hospitalizations.

Key Findings

1. Over a median follow-up of 48.5 months, the primary composite endpoint (death, disabling stroke, serious bleeding, or cardiac arrest) occurred in 8.0% of the ablation group versus 9.2% of the medical therapy group (HR 0.86; 95% CI, 0.65-1.15; P=0.30).

2. All-cause mortality was not significantly different between the groups (5.2% vs 6.1%; HR 0.85; 95% CI, 0.60-1.21; P=0.38).

3. Catheter ablation significantly reduced the composite secondary endpoint of death or cardiovascular hospitalization (51.7% vs 58.1%; HR 0.83; 95% CI, 0.74-0.93; P=0.001).

4. Atrial fibrillation recurrence was significantly lower in the ablation group compared to the medical therapy group (49.9% vs 69.5%; HR 0.52; 95% CI, 0.45-0.60; P<0.001).

Study Design

Design

RCT

Open-Label

Sample

2,204

Patients

Duration

48.5 mo

Median

Setting

10 countries

Population Symptomatic AF patients aged 65 years and older, or younger than 65 with 1 or more risk factors for stroke.

Intervention Catheter ablation (pulmonary vein isolation with additional ablation at investigator discretion).

Comparator Standard medical therapy (rate and/or rhythm control drugs based on contemporaneous guidelines).

Outcome Composite of death, disabling stroke, serious bleeding, or cardiac arrest.

Study Limitations

• High crossover rate (27.5% of patients assigned to medical therapy crossed over to ablation), which likely diluted the intention-to-treat treatment effect.

• Lower-than-expected primary event rates reduced the statistical power of the trial.

• Open-label design may have introduced bias, particularly for subjective decisions regarding hospitalization and crossover.

• Approximately 9.2% of patients assigned to the ablation arm never actually received the procedure.

Clinical Significance

The CABANA trial established that routine catheter ablation does not confer a survival or stroke-prevention benefit over medical therapy in a general symptomatic AF population. Its primary role remains symptom relief. However, the significant reduction in AF recurrence and cardiovascular hospitalizations supports ablation as a highly effective therapy for patients struggling with symptoms or medication intolerance. Providers must frame ablation as a quality-of-life intervention rather than a life-prolonging one for non-heart-failure AF patients.

Historical Context

Prior to CABANA, catheter ablation was widely accepted for symptom control in AF, but observational data and smaller trials suggested it might also improve survival and reduce stroke. As the largest trial of its kind, CABANA sought to definitively answer whether ablation improved hard clinical outcomes compared to standard antiarrhythmic or rate-control drugs. While its primary outcome was neutral, its results aligned with previous rhythm-control trials (like AFFIRM) which showed no survival advantage for rhythm control strategies overall, though later studies (like EAST-AFNET 4) would show benefit for very early rhythm control, and CASTLE-AF showed mortality benefit specifically in patients with heart failure.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the foundational pathophysiological mechanism by which catheter ablation treats atrial fibrillation, and why did the CABANA trial use an 'intention-to-treat' analysis as its primary statistical approach rather than grouping patients by the treatment they actually received?

Key Response

This tests the student's understanding of pulmonary vein isolation (eliminating ectopic electrical triggers) as the primary mechanism of AF ablation. It also introduces the vital epidemiological concept of intention-to-treat (ITT) analysis, which preserves randomization and prevents selection bias, even when patients cross over to the other treatment arm.

Resident

Given that the CABANA trial showed no significant mortality or stroke benefit for catheter ablation over medical therapy in the primary analysis, how does this outcome influence your shared decision-making process and treatment goals for a patient with highly symptomatic, drug-refractory atrial fibrillation?

Key Response

Residents must learn to translate trial data into patient counseling. The rationale emphasizes that while ablation does not guarantee a longer life or stroke prevention based on CABANA's ITT analysis, it significantly reduces AF recurrence and improves quality of life, making symptom relief the primary, evidence-based goal of the procedure.

Fellow

The CABANA trial experienced a 27.5% crossover rate from the medical therapy arm to the ablation arm. How does this substantial crossover complicate the interpretation of the intention-to-treat primary outcome, and how do you clinically reconcile the negative ITT results with the secondary 'as-treated' analysis that suggested a mortality benefit?

Key Response

Fellows need to navigate complex trial dynamics. High crossover dilutes the treatment effect in an ITT analysis, potentially driving a false negative (Type II error). However, an 'as-treated' analysis breaks randomization, introducing confounding (e.g., healthier patients might cross over to ablation). Fellows must balance these biases when interpreting the true efficacy of ablation.

Attending

In an era of intense scrutiny over procedural costs and healthcare resource utilization, how do you justify prioritizing catheter ablation for AF to trainees and hospital administrators when the CABANA trial failed to demonstrate a hard cardiovascular outcome benefit?

Key Response

Attendings must advocate for appropriate therapies while managing systemic costs. The rationale lies in synthesizing CABANA's secondary findings (reduced cardiovascular hospitalizations and AF recurrence) alongside separate quality-of-life sub-studies, teaching that reducing long-term healthcare utilization and dramatically improving patient function are highly valuable endpoints despite a negative primary mortality outcome.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The CABANA trial's primary endpoint event rate was lower than initially anticipated, prompting a mid-trial protocol amendment that expanded the primary composite endpoint to include cardiac arrest. From a methodological standpoint, how does amending a primary endpoint during an ongoing trial affect statistical power, alpha spending, and the overall robustness of the null hypothesis testing?

Key Response

This addresses advanced methodological vulnerabilities. Changing the endpoint mid-stream to inflate event rates can introduce bias, complicate the interpretation of the original power calculation, and risk alpha inflation, challenging the purist interpretation of the trial's statistical validity and generalizability.

Journal Editor

As a peer reviewer evaluating the CABANA manuscript, how would you address the authors' potential emphasis on statistically significant secondary endpoints (like AF recurrence) and per-protocol analyses in the context of a strictly negative intention-to-treat primary endpoint to prevent 'spin'?

Key Response

Editors must rigorously enforce CONSORT guidelines. The rationale highlights the editorial responsibility to ensure the abstract and conclusion remain anchored to the primary ITT outcome, preventing authors from inappropriately elevating secondary or unrandomized observational (as-treated) findings to salvage a 'positive' narrative from a negative trial.

Guideline Committee

How should the CABANA trial's primary and secondary findings influence the ACC/AHA/HRS atrial fibrillation guidelines regarding the Class of Recommendation for catheter ablation, specifically addressing whether ablation should be recommended for survival benefit versus symptom control?

Key Response

Guideline committees must stratify evidence rigidly. Because the primary composite endpoint was negative, CABANA supports maintaining catheter ablation as a Class I recommendation strictly for symptom control and quality of life improvement in drug-refractory patients, explicitly preventing an upgrade to a recommendation based on survival or stroke prevention in the general AF population.

Clinical Landscape

Noteworthy Related Trials

2002

AFFIRM Trial

n = 4,060 · NEJM

Tested

Rhythm-control strategy (antiarrhythmic drugs or cardioversion)

Population

Patients with atrial fibrillation and high risk for stroke or death

Comparator

Rate-control strategy

Endpoint

Overall mortality

Key result: There was no significant survival advantage with the rhythm-control strategy compared to rate control, and rhythm control had higher rates of hospitalization and adverse drug effects.

2018

CASTLE-AF Trial

n = 363 · NEJM

Tested

Catheter ablation

Population

Patients with atrial fibrillation and coexisting heart failure with reduced ejection fraction

Comparator

Medical therapy (rate or rhythm control)

Endpoint

Composite of all-cause mortality or hospitalization for worsening heart failure

Key result: Catheter ablation significantly reduced the rate of the primary composite endpoint of death or heart failure hospitalization compared to medical therapy.

2020

EAST-AFNET 4

n = 2,789 · NEJM

Tested

Early rhythm-control therapy (antiarrhythmic drugs or catheter ablation)

Population

Patients with recently diagnosed atrial fibrillation and concomitant cardiovascular conditions

Comparator

Usual care (primarily rate control)

Endpoint

Composite of cardiovascular death, stroke, or hospitalization for worsening heart failure or acute coronary syndrome

Key result: Early rhythm-control therapy was associated with a significantly lower risk of adverse cardiovascular outcomes than usual care.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis